Commercial considerations for raw materials in the cell and gene therapy industry

In by

Spotlight Article


Cell & Gene Therapy Raw Materials: Getting it Right from the Start

Dr Jon A Rowley


Jon A Rowley, is the Founder and Chief Technology Officer of RoosterBio, Inc. Jon started RoosterBio in 2013 as part of his personal quest of having the biggest impact possible on the commercial translation of technologies that incorporate living cells, including cellular therapies, engineered tissues and tomorrow’s medical devices. Jon holds a PhD from the University of Michigan in Biomedical Engineering and has authored over 35 peer reviewed manuscripts and 20 issued or pending patents related to biomaterials development, tissue engineering and cellular therapy. Jon started his industry career at BD as a scientist and R&D manager in a Cell & Tissue Technologies group focused on applying high throughput screening technologies to cell therapy media development and tissue engineering. Jon then contributed to the clinical development of Aastrom Biosciences’ Tissue Repair Cell product, where he was Sr Manager of Process Development responsible for manufacturing process improvements and cell delivery to the patient. Jon most recently spent 5 years as Director of Innovation and Process Development in Lonza’s Cell Therapy CMO business, and currently resides in Walkersville, MD with his wonderful wife and their 3 young children.

DOI: 10.18609/cgti.2017.022
Citation: Cell Gene Therapy Insights 2017; 3(3), 171-174.
Open access

This content is restricted to registered users. Click here to Register or Login here.